Review
Oncology
Marjukka Pollari, Suvi-Katri Leivonen, Sirpa Leppa
Summary: Testicular diffuse large B-cell lymphoma (T-DLBCL) is a rare and aggressive lymphoma that mainly affects elderly men, with a high relapse rate. It presents in an immune-privileged site of the testis, with unique biology and immune-related characteristics. Studies on the tumor microenvironment and immune checkpoint inhibitors show promising results for the treatment of T-DLBCL.
Review
Hematology
Eliza A. Hawkes, Allison Barraclough, Laurie H. Sehn
Summary: Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, has a good prognosis in limited-stage DLBCL (LS-DLBCL) patients. Recent studies have provided new insights and strategies for the treatment of LS-DLBCL, including the use of PET scans and clinical trials. However, there is currently no standard definition for LS-DLBCL, and treatment strategies vary across studies, posing challenges in interpretation.
Article
Oncology
Shi Qiu, Yizhen Liu, Ailing Gui, Zuguang Xia, Wen Liu, Juan J. Gu, Ji Zuo, Ling Yang, Qunling Zhang
Summary: OTUD7B is overexpressed in DLBCL and associated with better overall survival. Chidamide can up-regulate OTUD7B expression and synergistically enhance the effect of doxorubicin in DLBCL cell lines.
Article
Hematology
Waleed Alduaij, Brett Collinge, Susana Ben-Neriah, Aixiang Jiang, Laura K. Hilton, Merrill Boyle, Barbara Meissner, Lauren Chong, Tomoko Miyata-Takata, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Andrew Lytle, Kerry J. Savage, Diego Villa, Alina S. Gerrie, Ciara L. Freeman, Randy D. Gascoyne, Joseph M. Connors, Ryan D. Morin, Laurie H. Sehn, Andrew J. Mungall, Christian Steidl, David W. Scott
Summary: This study found that the molecular heterogeneity of DLBCL leads to variable outcomes with immunochemotherapy. DZsig expression extends beyond HGBCL-DH-BCL2 and captures a poor-prognosis DLBCL subgroup with short DTI, including patients unidentifiable by routine FISH testing, that should be considered for treatment intensification or novel therapies in prospective trials.
Article
Medicine, General & Internal
Herve Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, M. Trneny, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan M. Bergua-Burgues, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles
Summary: In untreated intermediate-risk or high-risk DLBCL patients, those who received pola-R-CHP had a lower risk of disease progression, relapse, or death compared to those who received R-CHOP. Overall survival and safety profiles were similar between the two groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Hematology
Wendan Xu, Philipp Berning, Georg Lenz
Summary: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous diagnostic category, with roughly one-third of patients not cured by standard treatments. BCR signaling and the PI3K pathway are proposed as potential targets for the treatment of DLBCL patients.
Article
Oncology
Reena Nair, Dinesh Bhurani, Senthil Rajappa, Asha Kapadia, Rakesh Reddy Boya, Subramanian Sundaram, Hari Menon, Ganapathi S. Raman, Arun Seshachalam, Ramesh Nimmagadda
Summary: This study analyzed the clinical characteristics, prognosis, comorbidities, and treatment response of diffuse large B-cell lymphoma (DLBCL) patients. The results showed that DLBCL is the most common subtype of lymphoma and can be cured with standard anthracycline- and rituximab-based therapies.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Xianggui Yuan, Xian Li, Yurong Huang, Xueli Jin, Hui Liu, Aiqi Zhao, Weiping Zhang, Wenbin Qian, Yun Liang
Summary: This study evaluated the efficacy and safety of zanubrutinib plus salvage chemotherapy in R/R DLBCL patients and found that it showed high efficacy and manageable tolerability. Additionally, CAR-T cell therapy may be a priority strategy for poor responders to BTKi-based treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Lars Kurch, Andreas Huettmann, Thomas W. Georgi, Jan Rekowski, Osama Sabri, Christine Schmitz, Regine Kluge, Ulrich Duehrsen, Dirk Hasenclever
Summary: In diffuse large B-cell lymphoma, continuous scales such as qPET and Delta SUVmax are more suitable for predicting treatment outcomes based on interim PET scans compared to the ordinal Deauville scale. The positive predictive value curves for qPET and Delta SUVmax were found to be similar, with both methods identifying less than 15% of patients as poor responders. The study suggests that continuous scales offer more accurate outcome predictions in this context.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Review
Oncology
Maria Huguet, Jose-Tomas Navarro, Jose Molto, Josep-Maria Ribera, Gustavo Tapia
Summary: Non-Hodgkin lymphoma (NHL) is a common HIV-related neoplasm, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype. DLBCL in people with HIV presents with aggressive characteristics. The introduction of combined antiretroviral therapy (cART) and the use of cART with chemotherapy have significantly improved the prognosis for people with HIV and DLBCL, approaching that of the general population.
Article
Oncology
Boram Lee, Hyunwoo Lee, Junhun Cho, Sang Eun Yoon, Seok Jin Kim, Woong-Yang Park, Won Seog Kim, Young Hyeh Ko
Summary: Genetic mechanisms underlying treatment resistance in recurrent/refractory diffuse large B-cell lymphoma (rrDLBCL) were explored through targeted deep sequencing, identifying key gene mutations associated with resistance and potential candidate genes for future treatment strategies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Pattamaporn Boonlerd, Adisak Tantiworawit, Lalita Norasetthada, Chatree Chai-Adisaksopha, Teerachat Punnachet, Nonthakorn Hantrakun, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Sasinee Hantrakool, Ekarat Rattarittamrong
Summary: The efficacy of salvage chemotherapy using ESHAP and DICE regimens for relapsed or refractory DLBCL showed no significant difference in terms of two-year PFS, two-year OS, and ORR. The DICE regimen exhibited fewer renal adverse events compared to ESHAP.
ANNALS OF MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
Summary: This study compared the prognoses of hepatitis B virus (HBV)-associated diffuse large B-cell lymphoma (DLBCL) patients receiving antiviral treatment and HBV-unassociated DLBCL patients. The results showed that HBV-associated DLBCL patients receiving antiviral treatment had significantly longer time-to-progression and overall survival after R-CHOP treatment.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Article
Oncology
Jinrong Zhao, Yan Zhang, Wei Wang, Wei Zhang, Daobin Zhou
Summary: Pneumonia is a major life-threatening complication after chemotherapy in patients with DLBCL, and risk factors include pulmonary involvement, higher Eastern Cooperative Oncology Group score, and hypoalbuminemia. Researchers have developed a prediction model based on these factors, which can aid in the development of individualized strategies for preventing and treating post-chemotherapy pneumonia in DLBCL patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Rong Shen, Di Fu, Lei Dong, Mu-Chen Zhang, Qing Shi, Zi-Yang Shi, Shu Cheng, Li Wang, Peng-Peng Xu, Wei-Li Zhao
Summary: Genetic classification is essential for identifying genetic subtypes of DLBCL and guiding targeted therapy. The LymphPlex algorithm, based on mutations and rearrangements of specific genes, successfully identified seven distinct subtypes. The genetic subtypes showed different clinical outcomes and biological characteristics, providing potential targets for personalized treatment approaches.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Oncology
Marco Dicanio, Matteo Giaccherini, Alyssa Clay-Gilmour, Angelica Macauda, Juan Sainz, Mitchell J. Machiela, Malwina Rybicka-Ramos, Aaron D. Norman, Agata Tyczynska, Stephen J. Chanock, Torben Barington, Shaji K. Kumar, Parveen Bhatti, Wendy Cozen, Elizabeth E. Brown, Anna Suska, Eva K. Haastrup, Robert Z. Orlowski, Marek Dudzinski, Ramon Garcia-Sanz, Marcin Kruszewski, Joaquin Martinez-Lopez, Katia Beider, Elzbieta Iskierka-Jazdzewska, Matteo Pelosini, Sonja Berndt, Malgorzata Razny, Krzysztof Jamroziak, S. Vincent Rajkumar, Artur Jurczyszyn, Annette Juul Vangsted, Pilar Garrido Collado, Ulla Vogel, Jonathan N. Hofmann, Mario Petrini, Aleksandra Butrym, Susan L. Slager, Elad Ziv, Edyta Subocz, Graham G. Giles, Niels Frost Andersen, Grzegorz Mazur, Marzena Watek, Fabienne Lesueur, Michelle A. T. Hildebrandt, Daria Zawirska, Lene Hyldahl Ebbesen, Herlander Marques, Federica Gemignani, Charles Dumontet, Judit Varkonyi, Gabriele Buda, Arnon Nagler, Agnieszka Druzd-Sitek, Xifeng Wu, Katalin Kadar, Nicola J. Camp, Norbert Grzasko, Rosalie G. Waller, Celine Vachon, Federico Canzian, Daniele Campa
Summary: The aim of this study was to identify novel pleiotropic variants involved in multiple myeloma (MM) risk. Through analysis of 28,684 single nucleotide polymorphisms (SNPs), DNAJB4-rs34517439-A was found to be associated with an increased risk of developing MM.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
B. R. Shank, B. Primeaux, E. K. Yeung, S. B. Horowitz, I. Y. Lee, L. Roccograndi, L. Feng, G. P. Kaufman, H. C. Lee, E. E. Manasanch, K. K. Patel, R. Z. Orlowski, D. M. Weber, M. R. Becnel, S. K. Thomas
Summary: This retrospective analysis evaluated the safety and efficacy of hyperfractionated cyclophosphamide-dexamethasone (hyperCd) with or without carfilzomib and/or daratumumab as a potential treatment option for multiple myeloma. The study found that hyperCd-based therapy achieved rapid disease control, although hematologic toxicities were common but manageable.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Meletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Philippe Moreau
Summary: Based on the analysis of POLLUX, daratumumab in combination with lenalidomide and dexamethasone significantly prolonged progression-free survival in patients with relapsed or refractory multiple myeloma. The final analysis also showed that this combination therapy improved overall survival in these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Oren Pasvolsky, Denai R. Milton, Mikael Rauf, Sassine Ghanem, Adeel Masood, Ali H. Mohamedi, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Katy Rezvani, Richard Champlin, Elizabeth J. Shpall, Pei Lin, Muzaffar H. Qazilbash
Summary: A retrospective analysis showed that the presence and degree of clonal plasma cells (CPC) in the autograft were highly predictive of inferior progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM) patients undergoing autologous hematopoietic stem cell transplantation (autoHCT).
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Nianyi Li, Pei Lin, Zhuang Zuo, M. James You, Wen Shuai, Robert Orlowski, Elisabet E. Manasanch, Shaoying Li, Jie Xu, Sofia Garces, Fatima Zahra Jelloul, Zhenya Tang, Wei Wang, L. Jeffrey Medeiros, C. Cameron Yin
Summary: This study found that mutations in the RAS-MAPK pathway, such as KRAS, NRAS, and BRAF, are associated with poor prognosis in various cancers, but the results in myeloma are inconsistent. It is shown that RAS/BRAF-mutated myeloma patients have shorter survival time and are associated with higher tumor burden and complex genetic variations.
Editorial Material
Hematology
Ashwath Gurumurthi, Jason Westin, Marion Subklewe
Review
Chemistry, Medicinal
Upasana Ray, Robert Z. Orlowski
Summary: Multiple myeloma is often treated with monoclonal antibodies targeting specific markers or as antibody-drug conjugates. There are several approved antibodies for treatment, such as daratumumab and isatuximab targeting CD38, elotuzumab targeting Signaling lymphocytic activation molecule family member 7, and teclistamab targeting BCMA. Belantamab mafodotin is an ADC that gained attention but faced withdrawal due to negative Phase III results. Despite this setback, there are other ADCs in development targeting BCMA or other plasma cell surface markers. Overall, ADCs have potential as part of chemotherapy against myeloma.
Article
Hematology
Oren Pasvolsky, Denai R. Milton, Adeel Masood, Sophiya S. Sami, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Arsalan Saeed, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash
Summary: The optimal duration of Len maintenance for MM patients after autoHCT is uncertain. A retrospective analysis was conducted on MM patients who underwent upfront autoHCT followed by single-agent Len maintenance between 2005 and 2021. The results showed that longer maintenance duration, even beyond 5 years, was associated with improved survival. However, longer maintenance duration was also linked to a higher risk of developing a second primary malignancy (SPM).
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Oren Pasvolsky, Curtis Marcoux, Denai R. Milton, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Priti Tewari, Lindsay Crawford-Suber, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash
Summary: This study analyzed the data of 117 young adults with multiple myeloma (MM) undergoing autologous transplantation and found that auto-HCT had a favorable outcome for them. Furthermore, the survival of younger MM patients improved with the availability of novel anti-myeloma drugs in recent years. Depth of response following transplant was a key predictor of survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Medicine, General & Internal
P. G. Richardson, S. Trudel, R. Popat, M- Mateos, A. J. Vangsted, K. Ramasamy, J. Martinez-Lopez, H. Quach, R. Z. Orlowski, M. Arnao, S. Lonial, C. Karanes, C. Pawlyn, K. Kim, A. Oriol, J. G. Berdeja, P. Rodriguez Otero, I Casas-Aviles, A. Spirli, J. Poon, S. Li, J. Gong, L. Wong, M. Lamba, D. W. Pierce, M. Amatangelo, T. Peluso, P. Maciag, J. Katz, Michael Pourdehnad, Nizar J. Bahlis
Summary: In this study, patients with relapsed and refractory multiple myeloma received oral mezigdomide in combination with dexamethasone. The combination therapy showed promising efficacy in heavily pretreated patients with multiple myeloma, with treatment-related adverse events consisting mainly of myelotoxic effects.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Anath C. Lionel, Jason Westin
Summary: This review focuses on the recent practice-changing trials of anti-CD19 CAR T cell therapies in LBCL. The trials showed significant improvements in overall survival and event-free survival with axicabtagene ciloleucel and lisocabtagene maraleucel, suggesting a potential shift in the standard of care for LBCL. CAR T cell therapy was found to be effective as a second-line treatment for elderly and transplant-ineligible patients, and also showed promise as a first-line treatment for high-risk disease.
CURRENT ONCOLOGY REPORTS
(2023)
Article
Hematology
Peter M. Voorhees, Douglas W. Sborov, Jacob Laubach, Jonathan L. Kaufman, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A. Efebera, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Shira Dinner, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Saad Z. Usmani, Paul G. Richardson
Summary: In transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of daratumumab to RVd improved the depth of response and progression-free survival.
LANCET HAEMATOLOGY
(2023)
Article
Oncology
Sonia M. Setayesh, Libere J. Ndacayisaba, Kate E. Rappard, Valerie Hennes, Luz Yurany Moreno Rueda, Guilin Tang, Pei Lin, Robert Z. Orlowski, David E. Symer, Elisabet E. Manasanch, Stephanie N. Shishido, Peter Kuhn
Summary: This study demonstrates the applicability of single-cell high-definition liquid biopsy assay and imaging mass cytometry to characterize the proteomic profile of multiple myeloma. It identifies potential therapeutic targets and reveals the differential expression of clinical markers across different stages of the disease.
NPJ PRECISION ONCOLOGY
(2023)
Article
Hematology
Saurabh Chhabra, Natalie Callander, Nicole L. Watts, Luciano J. Costa, Bicky Thapa, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Larry D. Anderson, Susan Bal, Binod Dhakal, Nitya Nathwani, Nina Shah, Eva Medvedova, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Timothy Schmidt, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Bhagirathbhai Dholaria, R. Frank Cornell, James H. Jerkins, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Saad Z. Usmani, Paul G. Richardson, Peter M. Voorhees
Summary: For eligible patients with newly diagnosed multiple myeloma (NDMM), standard of care includes induction therapy followed by autologous stem cell transplantation (ASCT). Daratumumab as monotherapy and in combination treatment is approved across multiple lines of therapy for multiple myeloma (MM), and lenalidomide is an effective and commonly used agent for induction and maintenance therapy in MM. However, there is concern that lenalidomide and daratumumab given as induction therapy might impair mobilization of stem cells for ASCT.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Ethan P. Damron, Muzaffar H. Qazilbash, Penny Q. Fang, Susan Y. Wu, Bouthaina S. Dabaja, Gabriela Rondon, Chitra Hosing, Richard E. Champlin, Qaiser Bashir, Elizabeth J. Shpall, Mark K. Knafl, Hans C. Lee, Elisabet E. Manasanch, Krina Patel, Sheeba K. Thomas, Robert Z. Orlowski, Donna M. Weber, Chelsea C. Pinnix, Jillian R. Gunther
Summary: The primary treatment of multiple myeloma (MM) often includes systemic induction therapy (SIT) and autologous stem cell transplantation (ASCT). However, radiation therapy (RT) is sometimes avoided due to concerns about its effect on peripheral blood progenitor cell (PBPC) collection for ASCT. This study retrospectively examined the possible impact of RT on PBPC collection in MM patients. The results showed that RT prior to ASCT did not impair the successful collection of PBPCs.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
